-+ 0.00%
-+ 0.00%
-+ 0.00%

BioArctic reports 76% lower rate of Alzheimer's progression with Leqembi in three-year real-world study

PUBT·11/18/2026 16:19:25
Listen to the news
BioArctic reports 76% lower rate of Alzheimer's progression with Leqembi in three-year real-world study
  • BioArctic's partner Eisai presented three-year Leqembi real-world study results at CTAD in Boston on November 18, 2026.
  • The LEADER study included 560 patients across 13 US sites, showing slower progression to moderate or severe Alzheimer's dementia versus matched controls.
  • Most assessed patients remained stable or improved, with high treatment persistence.
  • Safety findings were consistent with other real-world experience; no amyloid-related imaging abnormalities were reported during subcutaneous maintenance treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via Cision (Ref. ID: 202611181117BITN____UKPR__EN_20261118-BIT-1229-0) on November 18, 2026, and is solely responsible for the information contained therein.